XIMINO (minocycline hydrochloride) · JOURNEY
XIMINO is FDA-approved to treat 1 condition (same as AMZEEQ).
Details
- Status
- Discontinued
- First Approved
- 2012-07-11
- Patent Cliff
- 2027
- Routes
- ORAL
- Dosage Forms
- CAPSULE, EXTENDED RELEASE
XIMINO Approval History
What XIMINO Treats
1 indicationsXIMINO is approved for 1 conditions since its original approval in 2012. These indications span multiple therapeutic areas including oncology, immunology, and more.
Same approved indications as AMZEEQ (same active ingredient).
Clinical Trial Registry
5 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06246396 | IRB202301939 2R01HL132448-05A1 | Ph 4 | recruiting | Antihypertensive Mechanisms of Minocycline in Resistant Hypertension |
| NCT05826912 APT-TBI-01 | APT-TBI-01 | Ph 2 | enrolling by invitation | Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury |
| NCT02203552 results posted | OSU-13165 NCI-2014-00851 | Ph 2 | completed | Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer |
| NCT02297412 results posted | RU221408I NCI-2016-01592, RU221408I | Ph 2 | completed | Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel |
| NCT04076098 | RP139-02/18 | Ph 4 | completed | Locally Delivered Minocycline in Advanced Periodontitis |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
XIMINO FDA Label Details
Indications & Usage
FDA Label (PDF)XIMINO is FDA-approved to treat 1 condition — same approved indications as AMZEEQ.
Pro Intelligence Preview
Deep insights for XIMINO
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2027
- • 45 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • Competitor tracking
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.